Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Molecular Templates stock

Learn how to easily invest in Molecular Templates stock.

Molecular Templates is a biotechnology business based in the US. Molecular Templates shares (MTEM) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Templates employs 224 staff and has a trailing 12-month revenue of around $35.1 million.

How to buy Molecular Templates stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – MTEM. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Molecular Templates stock price (NASDAQ: MTEM)

Use our graph to track the performance of MTEM stocks over time.

Molecular Templates shares at a glance

Information last updated 2023-01-25.
Latest market close$0.53
52-week range$0.31 - $3.64
50-day moving average $0.48
200-day moving average $0.89
Wall St. target price$10.13
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.38

Buy Molecular Templates stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Molecular Templates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Templates price performance over time

Historical closes compared with the close of $0.53 from 2023-01-27

1 week (2023-01-23) 6.00%
1 month (2022-12-30) 61.59%
3 months (2022-10-28) -15.87%
6 months (2022-07-29) -37.05%
1 year (2022-01-28) -82.09%
2 years (2021-01-29) -95.37%
3 years (2020-01-30) 13.93
5 years (2018-01-29) 10.78

Molecular Templates financials

Revenue TTM $35.1 million
Gross profit TTM $-45,968,000
Return on assets TTM -28.42%
Return on equity TTM -212.21%
Profit margin -230.47%
Book value $0.07
Market capitalisation $29.2 million

TTM: trailing 12 months

Molecular Templates share dividends

We're not expecting Molecular Templates to pay a dividend over the next 12 months.

Have Molecular Templates's shares ever split?

Molecular Templates's shares were split on a 1:11 basis on 1 August 2017. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Molecular Templates shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Molecular Templates shares which in turn could have impacted Molecular Templates's share price.

Molecular Templates share price volatility

Over the last 12 months, Molecular Templates's shares have ranged in value from as little as $0.31 up to $3.64. A popular way to gauge a stock's volatility is its "beta".

MTEM.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Templates's is 1.2236. This would suggest that Molecular Templates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Molecular Templates overview

Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc.

Frequently asked questions

What percentage of Molecular Templates is owned by insiders or institutions?
Currently 4.874% of Molecular Templates shares are held by insiders and 74.365% by institutions.
How many people work for Molecular Templates?
Latest data suggests 224 work at Molecular Templates.
When does the fiscal year end for Molecular Templates?
Molecular Templates's fiscal year ends in December.
Where is Molecular Templates based?
Molecular Templates's address is: 9301 Amberglen Boulevard, Austin, TX, United States, 78729
What is Molecular Templates's ISIN number?
Molecular Templates's international securities identification number is: US6085501095
What is Molecular Templates's CUSIP number?
Molecular Templates's Committee on Uniform Securities Identification Procedures number is: 885807107

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site